Pacific Biosciences of California, Inc. (PACB)Healthcare | Medical Devices | Menlo Park, United States | NasdaqGS
1.50 USD
0.00
(-0.080%) ⇩
(July 15, 2026, 12:25 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:21 a.m. EDT
The long-term investment case is severely compromised by deteriorating fundamentals and a brutal multi-year price trajectory. Despite the company's innovative sequencing technology, the financial reality is stark: the business is burning cash with negative operating margins, a massive debt load relative to equity, and a return on equity that is deeply negative. The price history confirms the market's rejection of the current business model, showing an 80% cumulative decline over the last nine years and two consecutive years of falling prices. This is not a value trap; it is a structural decline where the market has correctly priced out the lack of sustainable profitability and growth. In the short term, the stock remains a speculative gamble. While the price has recently bounced off lows, the technical setup is fragile, trading below key moving averages with high beta volatility amplifying the risk. The options market reflects this uncertainty, with traders buying protection against further drops rather than betting on a recovery. With no dividend to provide income and a balance sheet that requires constant capital raising to survive, the risk/reward profile is skewed heavily toward the downside. Investors should view this as a high-risk speculative vehicle rather than an investment opportunity. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.124798 |
| AutoTheta | 0.130466 |
| AutoETS | 0.130537 |
| AutoARIMA | 0.130538 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.335 |
| Excess Kurtosis | -1.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 29855.79 |
| Revenue per Share | 0.53 |
| Market Cap | 465,529,824 |
| Forward P/E | -3.78 |
| Beta | 2.29 |
| Profit Margins | -80.34% |
| Website | https://www.pacb.com |
As of July 11, 2026, 5:21 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly in the January 2027 expiration where out-of-the-money puts show significant open interest. Implied volatility is elevated on the downside side compared to the upside, suggesting a fear of further decline rather than a bullish breakout. The ATM anchor strikes see mixed flow, but the concentration of open interest at lower strikes indicates a 'floor' mentality among traders.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.006711364 |
| Address1 | 1,305 O’Brien Drive |
| All Time High | 53.69 |
| All Time Low | 0.85 |
| Ask | 1.92 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 4,992,050 |
| Average Daily Volume3 Month | 6,255,521 |
| Average Volume | 6,255,521 |
| Average Volume10Days | 4,992,050 |
| Beta | 2.289 |
| Bid | 1.08 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 0.008 |
| City | Menlo Park |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.4988 |
| Current Ratio | 5.654 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.535 |
| Day Low | 1.48 |
| Debt To Equity | 29,855.79 |
| Display Name | Pacific Biosciences of California |
| Earnings Call Timestamp End | 1,778,185,800 |
| Earnings Call Timestamp Start | 1,778,185,800 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -143,146,000 |
| Ebitda Margins | -0.89449 |
| Enterprise To Ebitda | -6.262 |
| Enterprise To Revenue | 5.601 |
| Enterprise Value | 896,328,512 |
| Eps Current Year | -0.5064 |
| Eps Forward | -0.3966 |
| Eps Trailing Twelve Months | -0.41 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 618 2699 |
| Fifty Day Average | 1.445 |
| Fifty Day Average Change | 0.053799987 |
| Fifty Day Average Change Percent | 0.037231825 |
| Fifty Two Week Change Percent | 0.6711364 |
| Fifty Two Week High | 2.73 |
| Fifty Two Week High Change | -1.2312 |
| Fifty Two Week High Change Percent | -0.450989 |
| Fifty Two Week Low | 1.09 |
| Fifty Two Week Low Change | 0.4088 |
| Fifty Two Week Low Change Percent | 0.37504587 |
| Fifty Two Week Range | 1.09 - 2.73 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,288,186,200,000 |
| Float Shares | 303,830,571 |
| Forward Eps | -0.3966 |
| Forward P E | -3.7791226 |
| Free Cashflow | -48,237,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 485 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.38327 |
| Gross Profits | 61,334,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08768 |
| Held Percent Institutions | 0.53812003 |
| Implied Shares Outstanding | 310,601,688 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. |
| Long Name | Pacific Biosciences of California, Inc. |
| Market | us_market |
| Market Cap | 465,529,824 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_11461617 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -128,576,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 467,455,540 |
| Number Of Analyst Opinions | 6 |
| Open | 1.51 |
| Operating Cashflow | -111,844,000 |
| Operating Margins | -1.02891 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 521 8000 |
| Previous Close | 1.5 |
| Price Eps Current Year | -2.9597158 |
| Price Hint | 4 |
| Price To Book | 187.34999 |
| Price To Sales Trailing12 Months | 2.909016 |
| Profit Margins | -0.80345 |
| Quick Ratio | 4.672 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0011999607 |
| Regular Market Change Percent | -0.07999738 |
| Regular Market Day High | 1.535 |
| Regular Market Day Low | 1.48 |
| Regular Market Day Range | 1.48 - 1.535 |
| Regular Market Open | 1.51 |
| Regular Market Previous Close | 1.5 |
| Regular Market Price | 1.4988 |
| Regular Market Time | 1,784,132,747 |
| Regular Market Volume | 1,734,167 |
| Return On Assets | -0.11965 |
| Return On Equity | -2.73554 |
| Revenue Growth | 0.001 |
| Revenue Per Share | 0.53 |
| Sand P52 Week Change | 0.2043345 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 310,601,688 |
| Shares Percent Shares Out | 0.1529 |
| Shares Short | 47,490,204 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 48,707,384 |
| Short Name | Pacific Biosciences of Californ |
| Short Percent Of Float | 0.1758 |
| Short Ratio | 7.15 |
| Source Interval | 15 |
| State | CA |
| Symbol | PACB |
| Target High Price | 3.0 |
| Target Low Price | 1.5 |
| Target Mean Price | 2.45833 |
| Target Median Price | 2.625 |
| Total Cash | 275,961,984 |
| Total Cash Per Share | 0.888 |
| Total Debt | 706,387,968 |
| Total Revenue | 160,030,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.70755 |
| Two Hundred Day Average Change | -0.20875001 |
| Two Hundred Day Average Change Percent | -0.12225118 |
| Type Disp | Equity |
| Volume | 1,734,167 |
| Website | https://www.pacb.com |
| Zip | 94,025 |